Cargando…

The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth

PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowers, Laura W., Lineberger, Claire G., Ford, Nikki A., Rossi, Emily L., Punjala, Arunima, Camp, Kristina K., Kimler, Bruce K., Fabian, Carol J., Hursting, Stephen D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394576/
https://www.ncbi.nlm.nih.gov/pubmed/30367332
http://dx.doi.org/10.1007/s10549-018-5021-6
_version_ 1783398926476378112
author Bowers, Laura W.
Lineberger, Claire G.
Ford, Nikki A.
Rossi, Emily L.
Punjala, Arunima
Camp, Kristina K.
Kimler, Bruce K.
Fabian, Carol J.
Hursting, Stephen D.
author_facet Bowers, Laura W.
Lineberger, Claire G.
Ford, Nikki A.
Rossi, Emily L.
Punjala, Arunima
Camp, Kristina K.
Kimler, Bruce K.
Fabian, Carol J.
Hursting, Stephen D.
author_sort Bowers, Laura W.
collection PubMed
description PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth. However, while preclinical studies have established that SDG and ENL affect measures of progression in models of triple-negative breast cancer (TNBC, a subset of ERα-negative disease), the molecular mechanisms underlying these effects remain unclear. METHODS: C57BL/6 mice were fed a control diet (control, 10% kcal from fat) or control diet + SDG (SDG, 100 mg/kg diet) for 8 weeks, then orthotopically injected with syngeneic E0771 mammary tumor cells (a model of TNBC); tumor growth was monitored for 3 weeks. The role of reduced NF-κB signaling in SDG’s anti-tumor effects was explored in vitro via treatment with the bioactive SDG metabolite ENL. In addition to the murine E0771 cells, the in vitro studies utilized MDA-MB-231 and MCF-7 cells, two human cell lines which model the triple-negative and luminal A breast cancer subtypes, respectively. RESULTS: SDG supplementation in the mice significantly reduced tumor volume and expression of phospho-p65 and NF-κB target genes (P < 0.05). Markers of macrophage infiltration were decreased in the distal-to-tumor mammary fat pad of mice supplemented with SDG relative to control mice (P < 0.05). In vitro, ENL treatment inhibited viability, survival, and NF-κB activity and target gene expression in E0771, MDA-MB-231, and MCF-7 cells (P < 0.05). Overexpression of Rela attenuated ENL’s inhibition of E0771 cell viability and survival. CONCLUSIONS: SDG reduces tumor growth in the E0771 model of TNBC, likely via a mechanism involving inhibition of NF-κB activity. SDG could serve as a practical and effective adjuvant treatment to reduce recurrence, but greater understanding of its effects is needed to inform the development of more targeted recommendations for its use. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-018-5021-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6394576
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-63945762019-03-15 The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth Bowers, Laura W. Lineberger, Claire G. Ford, Nikki A. Rossi, Emily L. Punjala, Arunima Camp, Kristina K. Kimler, Bruce K. Fabian, Carol J. Hursting, Stephen D. Breast Cancer Res Treat Preclinical Study PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth. However, while preclinical studies have established that SDG and ENL affect measures of progression in models of triple-negative breast cancer (TNBC, a subset of ERα-negative disease), the molecular mechanisms underlying these effects remain unclear. METHODS: C57BL/6 mice were fed a control diet (control, 10% kcal from fat) or control diet + SDG (SDG, 100 mg/kg diet) for 8 weeks, then orthotopically injected with syngeneic E0771 mammary tumor cells (a model of TNBC); tumor growth was monitored for 3 weeks. The role of reduced NF-κB signaling in SDG’s anti-tumor effects was explored in vitro via treatment with the bioactive SDG metabolite ENL. In addition to the murine E0771 cells, the in vitro studies utilized MDA-MB-231 and MCF-7 cells, two human cell lines which model the triple-negative and luminal A breast cancer subtypes, respectively. RESULTS: SDG supplementation in the mice significantly reduced tumor volume and expression of phospho-p65 and NF-κB target genes (P < 0.05). Markers of macrophage infiltration were decreased in the distal-to-tumor mammary fat pad of mice supplemented with SDG relative to control mice (P < 0.05). In vitro, ENL treatment inhibited viability, survival, and NF-κB activity and target gene expression in E0771, MDA-MB-231, and MCF-7 cells (P < 0.05). Overexpression of Rela attenuated ENL’s inhibition of E0771 cell viability and survival. CONCLUSIONS: SDG reduces tumor growth in the E0771 model of TNBC, likely via a mechanism involving inhibition of NF-κB activity. SDG could serve as a practical and effective adjuvant treatment to reduce recurrence, but greater understanding of its effects is needed to inform the development of more targeted recommendations for its use. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-018-5021-6) contains supplementary material, which is available to authorized users. Springer US 2018-10-26 2019 /pmc/articles/PMC6394576/ /pubmed/30367332 http://dx.doi.org/10.1007/s10549-018-5021-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Preclinical Study
Bowers, Laura W.
Lineberger, Claire G.
Ford, Nikki A.
Rossi, Emily L.
Punjala, Arunima
Camp, Kristina K.
Kimler, Bruce K.
Fabian, Carol J.
Hursting, Stephen D.
The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth
title The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth
title_full The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth
title_fullStr The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth
title_full_unstemmed The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth
title_short The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth
title_sort flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses nfκb signaling, and inhibits mammary tumor growth
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394576/
https://www.ncbi.nlm.nih.gov/pubmed/30367332
http://dx.doi.org/10.1007/s10549-018-5021-6
work_keys_str_mv AT bowerslauraw theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT linebergerclaireg theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT fordnikkia theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT rossiemilyl theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT punjalaarunima theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT campkristinak theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT kimlerbrucek theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT fabiancarolj theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT hurstingstephend theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT bowerslauraw flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT linebergerclaireg flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT fordnikkia flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT rossiemilyl flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT punjalaarunima flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT campkristinak flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT kimlerbrucek flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT fabiancarolj flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth
AT hurstingstephend flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth